# A Clinical Study of Purinostat Mesylate for Injection in Patients With Advanced Solid Tumors

Source: https://onco.cc/trials/nct06431243/  
OnCo record `nct06431243` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Purinostat in advanced solid tumours, run by Chengdu Zenitar Biomedical Technology Co., Ltd, now recruiting.

## Summary

A Clinical Study of Purinostat Mesylate for Injection in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06431243 by Chengdu Zenitar Biomedical Technology Co., Ltd, with 132 participants planned, started 2024-05-08 and due to reach its primary completion in 2026-05-01. Interventions recorded: A0/B0 group Purinostat Mesylate 11.2mg/m2, A0/B0 group Purinostat Mesylate 15mg/m2, A group Purinostat Mesylate 6mg/m2, A group Purinostat Mesylate 8.4mg/m2, A group Purinostat Mesylate 11.2mg/m2 and A group Purinostat Mesylate 15 mg/m2.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06431243
- Phase: 1/2
- Setting: An Open, Multicenter Phase Ib/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of the Purinostat Mesylate for Injection in Combination Therapy for Advanced Solid Tumors
- Sponsor: Chengdu Zenitar Biomedical Technology Co., Ltd
- Enrolled: 132

## Sources

- ClinicalTrials.gov NCT06431243: https://clinicaltrials.gov/study/NCT06431243

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Purinostat](https://onco.cc/drugs/purinostat/)
- companies: [Chengdu Zenitar Biomedical Technology](https://onco.cc/companies/chengdu-zenitar-biomedical-technology/)

---
JSON: https://onco.cc/api/v1/entities/nct06431243.json